GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Institutional Ownership

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Institutional Ownership : 83.26% (As of Apr. 26, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Ligand Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ligand Pharmaceuticals's institutional ownership is 83.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ligand Pharmaceuticals's Insider Ownership is 11.42%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ligand Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 68.46%.


Ligand Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Ligand Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Institutional Ownership Chart

Ligand Pharmaceuticals Historical Data

The historical data trend for Ligand Pharmaceuticals can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 84.65 84.99 85.89 85.92 83.48 84.21 87.21 87.69 85.47 83.26

Ligand Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Headlines

From GuruFocus

Ligand to Report Fourth Quarter Financial Results on February 22

By Business Wire Business Wire 02-06-2023

Ligand Provides Highlights from its Investor and Analyst Day Event

By Business Wire Business Wire 12-13-2022